CCL2 and glioblastoma: In a complementary experiment, we observed that CM derived from GBM 95 (GBM CM) in the bottom chamber induced microglial migration and that this effect was inhibited by GBM CM-pretreatment with a commercially available anti-CCL21 neutralizing antibody (CCL2-bAbs) (Fig. 2j).